Efficacy and safety of PF-00299804 (PF299). an oral, irreversible, part-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC)

被引：17
|
作者：
Mok, T.
Spigel, D. R.
Park, K.
Socinski, M. A.
Tung, S. Y.
Kim, D.
Borzillo, G.
Zhang, H.
O'Connell, J. P.
Janne, P. A.
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[6] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[7] Pfizer Inc, New London, CT USA
[8] Pfizer Res & Dev Co Ltd, Shanghai, Peoples R China
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7537
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
    Lin, Liping
    Zhao, Juanjuan
    Hu, Jiazhu
    Huang, Fuxi
    Han, Jianjun
    He, Yan
    Cao, Xiaolong
    JOURNAL OF CANCER, 2018, 9 (03): : 528 - 534
  • [32] COST-EFFECTIVENESS OF FIRST LINE TYROSINE KINASE INHIBITOR TREATMENT IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATED ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A MARKOV MODEL
    Borget, Isabelle
    Vergnenegre, Alain
    Chouaid, Christos
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1269 - S1269
  • [33] The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
    Chen, Dougfang
    Chu, Tianqing
    Chang, Qing
    Zhang, Yanwei
    Xiong, Liwen
    Qiao, Rong
    Teng, Jiajun
    Han, Baohui
    Zhong, Runbo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (09)
  • [34] Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer
    He, Wenjie
    Li, Wenhui
    Jiang, Bo
    Chang, Li
    Jin, Congguo
    Tu, Changlin
    Li, Yunfen
    ONCOTARGETS AND THERAPY, 2016, 9 : 7515 - 7520
  • [35] EFFICACY OF CHEMOTHERAPY (CHT) BEYOND TYROSINE KINASES INHIBITORS (TKI) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) UNSELECTED FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION
    Trenta, P.
    Iacovelli, R.
    Palazzo, A.
    Pellegrino, D.
    Mosillo, C.
    Rubini, F.
    Prete, A.
    Magri, V.
    De Benedetto, A.
    Cortesi, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 440 - 440
  • [36] KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts)
    Metro, Giulio
    Duranti, Simona
    Chiari, Rita
    Bennati, Chiara
    Molica, Carmen
    Curra, Maria Francesca
    Scafati, Chiara
    Siggillino, Annamaria
    Flacco, Antonella
    Marcomigni, Luca
    Ludovini, Vienna
    Minotti, Vincenzo
    Crino, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Rossi, Antonio
    Pasquale, Raffaella
    Esposito, Claudia
    Normanno, Nicola
    CANCER TREATMENT REVIEWS, 2013, 39 (05) : 489 - 497
  • [38] A PILOT STUDY OF A STEROID SULPHATASE INHIBITOR (BN83495) IN PATIENTS WITH RASH DUE TO TREATMENT WITH AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)
    Mileshkin, Linda
    Mccormack, Chris
    Michael, Michael
    Solomon, Ben
    Urban, Damien
    Link, Emma
    Cowan, Linda
    Zalcberg, John
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1020 - S1020
  • [39] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    CANCER RESEARCH, 2006, 66 (08)
  • [40] Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptor
    Iuchi, T.
    Shingyoji, M.
    Itakura, M.
    Hasegawa, Y.
    Yoshida, Y.
    Ikegami, S.
    Setoguchi, T.
    Ashinuma, H.
    ANNALS OF ONCOLOGY, 2016, 27
12345